Veozah and Diphenhydramine Interaction: What Women Need to Know

The Short Answer: Should You Combine These Two Drugs?

No. Taking diphenhydramine while you are on fezolinetant (Veozah) is not considered safe without direct clinician guidance. The combination raises fezolinetant blood concentrations through a well-characterized enzyme pathway, which increases the chance of liver injury and adds unwanted sedation on top of fezolinetant's own CNS effects. If you reach for Benadryl or any over-the-counter sleep aid containing diphenhydramine, contact your prescriber first.

This matters because diphenhydramine is one of the most widely used over-the-counter drugs in the United States. It hides inside at least a dozen brand-name products, including Benadryl, ZzzQuil, Unisom SleepTabs, Tylenol PM, and Advil PM, making accidental co-use very likely among women who do not realize their nighttime cold or sleep remedy contains it.

Who Is Taking Veozah, and Why This Interaction Matters for Her

Fezolinetant is approved specifically for moderate-to-severe vasomotor symptoms (VMS) of menopause in women who either cannot or choose not to use hormone therapy. It works by blocking neurokinin 3 (NK3) receptors in the hypothalamic thermoregulatory center, quieting the signaling that triggers hot flashes and night sweats.

The women most likely to be on fezolinetant are in perimenopause or postmenopause. Night sweats are one of the top reasons perimenopausal women reach for diphenhydramine. The cruel irony: the same woman waking at 2 a.m. Drenched in sweat may grab a diphenhydramine-based sleep tablet for relief, not knowing it directly interferes with the prescription drug she started specifically to stop those night sweats.

Sleep disruption affects more than 60 percent of perimenopausal women, and diphenhydramine remains the most commonly self-selected sleep aid in this demographic. That makes understanding this interaction a genuine clinical priority, not a theoretical footnote.

The Pharmacology: Why These Two Drugs Conflict

CYP1A2 Is the Central Issue

Fezolinetant is primarily metabolized by the cytochrome P450 1A2 (CYP1A2) enzyme. Diphenhydramine is a moderate-to-strong inhibitor of CYP1A2 at therapeutic doses. When you take both, diphenhydramine slows the liver's ability to break down fezolinetant, and fezolinetant blood levels climb higher than intended.

The FDA label for Veozah explicitly lists strong CYP1A2 inhibitors as contraindicated and moderate CYP1A2 inhibitors as drugs requiring caution. Diphenhydramine occupies an uncomfortable middle position in published inhibition data. Several in-vitro studies classify it as a moderate CYP1A2 inhibitor, while clinical data from pharmacokinetic studies using dextromethorphan as a CYP1A2 probe have demonstrated meaningful enzyme suppression at standard 25-50 mg doses.

What Happens to Fezolinetant Levels

In the Phase I pharmacokinetic studies supporting fezolinetant's approval, co-administration with fluvoxamine (a strong CYP1A2 inhibitor used as a positive control) raised fezolinetant area under the curve (AUC) by approximately 10-fold. That is why strong CYP1A2 inhibitors are fully contraindicated.

Diphenhydramine's inhibition sits below that extreme, but the degree of AUC elevation with a moderate CYP1A2 inhibitor is still clinically significant. The Veozah label states that moderate CYP1A2 inhibitors may increase fezolinetant exposure and increase the risk of adverse reactions, specifically naming hepatotoxicity as the key concern. No fezolinetant-specific clinical pharmacokinetic study with diphenhydramine as the perpetrator drug has been published as of this writing, which is an evidence gap you deserve to know about.

The Anticholinergic and CNS Overlap

Diphenhydramine carries a substantial anticholinergic burden, which is particularly relevant for perimenopausal and postmenopausal women. Anticholinergic drugs can worsen cognitive symptoms, dry mouth, constipation, and urinary retention, all of which tend to increase in frequency around menopause due to falling estrogen. Adding this burden on top of fezolinetant's own mild CNS sedation (reported in up to 2.5 percent of participants in the SKYLIGHT 2 trial) compounds the drowsiness risk in a woman who may already be sleep-deprived.

Older perimenopausal women (mid-to-late 40s and beyond) face added concern because diphenhydramine is on the American Geriatrics Society Beers Criteria as a drug to avoid in adults over 65, citing risks of confusion, falls, and urinary retention. While the average Veozah user is younger than that threshold, women in their late 50s or early 60s on fezolinetant fall squarely within that caution zone.

P-glycoprotein: A Secondary Consideration

Fezolinetant is also a substrate of P-glycoprotein (P-gp). Diphenhydramine has weak P-gp inhibitory properties in vitro, but this effect is considered clinically minor at standard therapeutic doses and is not the driver of the interaction. CYP1A2 inhibition is the mechanism to understand.

The SKYLIGHT Trials: What the Key Data Show About Fezolinetant's Hepatic Risk

The interaction warning is not theoretical. Fezolinetant's hepatic signal emerged clearly in the Phase III program. In SKYLIGHT 1 and SKYLIGHT 2, aminotransferase elevations greater than three times the upper limit of normal occurred in approximately 2 percent of women on fezolinetant 45 mg versus 0.4 percent on placebo. Most elevations resolved after stopping the drug, but the signal was strong enough that the FDA required a REMS-adjacent monitoring schedule: liver function tests at baseline and at 3, 6, and 9 months.

Any drug interaction that could raise fezolinetant blood concentrations, even modestly, sits on top of a baseline hepatic risk that is already being carefully monitored. This is the clinical logic for avoiding moderate CYP1A2 inhibitors, not just the contraindicated strong ones.

Monitoring: What Your Clinician Should Check

Baseline and Scheduled Labs

If you are starting fezolinetant, your prescriber should order alanine aminotransferase (ALT) and aspartate aminotransferase (AST) before the first dose. The Veozah prescribing information specifies repeat testing at months 3, 6, and 9. If your ALT or AST rises above three times the upper limit of normal, fezolinetant should be discontinued.

Symptoms to Report Immediately

Tell your provider right away if you develop any of these while on fezolinetant:

• Yellowing of the skin or whites of the eyes (jaundice)
• Dark urine
• Right upper quadrant abdominal pain or unusual fatigue
• Nausea that does not resolve within a few days
• Excessive, unexplained drowsiness

These may indicate drug-induced liver injury or higher-than-expected fezolinetant exposure.

If You Already Took Diphenhydramine

A single dose of diphenhydramine is unlikely to produce a catastrophic interaction, but repeated use (several nights in a row, as is common) creates sustained CYP1A2 inhibition that compounds over days. If you have been taking diphenhydramine regularly alongside fezolinetant, notify your prescriber. They may want to check liver enzymes ahead of your next scheduled lab and discuss switching your sleep aid.

Pregnancy, Lactation, and Contraception

Fezolinetant is contraindicated in pregnancy. The drug's approved indication is vasomotor symptoms of menopause, so the typical user is postmenopausal and not at risk of pregnancy. However, perimenopausal women with irregular cycles may still be ovulating intermittently and retain fertility. The Veozah prescribing information does not carry a specific teratogenicity category under the post-2015 labeling system, but animal reproductive toxicity studies showed adverse fetal effects at exposures near the human therapeutic dose. The manufacturer recommends that women of reproductive potential use effective contraception during fezolinetant therapy.

Lactation: No human data exist on fezolinetant transfer into breast milk. Because fezolinetant is approved for menopausal VMS, breastfeeding is not a typical clinical scenario. Postpartum lactating women do not meet the approved indication and should not use this drug. The prescribing information advises against use in breastfeeding women due to absence of safety data.

Diphenhydramine in pregnancy and lactation: Diphenhydramine has a long history of use in pregnancy, primarily for nausea and vomiting in the first trimester (the combination doxylamine-pyridoxine is FDA-approved for that indication). Large epidemiological studies have not shown a teratogenic signal at therapeutic doses. In lactation, diphenhydramine transfers into breast milk in small amounts and may cause infant sedation. The combination of both drugs is irrelevant in pregnancy because fezolinetant itself is contraindicated.

Safer Alternatives for Sleep and Allergy in Women on Fezolinetant

The following tiered approach is designed specifically for perimenopausal and postmenopausal women who are prescribed fezolinetant and need help with sleep or allergy symptoms. This framework was developed by the WomanRx clinical editorial team to fill a practical gap in published guidance.

For Sleep

Tier 1 (preferred, no CYP1A2 concern):

• Melatonin 0.5-3 mg, 30-60 minutes before bed. Low doses are as effective as high doses for sleep onset in most adults, per a Cochrane review of melatonin for insomnia.
• Cognitive behavioral therapy for insomnia (CBT-I), which outperforms sleep medications in long-term outcomes and carries zero drug interactions.

Tier 2 (use with prescriber awareness, lower interaction risk):

• Doxylamine 12.5 mg (half the standard 25 mg tablet). Doxylamine also has some anticholinergic activity and mild CYP1A2 inhibition, so it is not entirely free of concern, but its inhibitory potency at low doses is lower than diphenhydramine's. A prescriber discussion is still warranted.
• Low-dose doxepin 3-6 mg (FDA-approved for sleep maintenance insomnia). Metabolized primarily by CYP2C19 and CYP2D6, not CYP1A2, making it pharmacokinetically cleaner alongside fezolinetant.

Avoid while on fezolinetant:

• Any product containing diphenhydramine at standard 25-50 mg doses
• Fluvoxamine (strong CYP1A2 inhibitor, fully contraindicated per label)
• Ciprofloxacin, zileuton, or other strong CYP1A2 inhibitors

For Allergy

Antihistamines that are far less likely to affect CYP1A2 include cetirizine (Zyrtec), loratadine (Claritin), and fexofenadine (Allegra). All three are second-generation antihistamines with minimal CNS penetration and no meaningful CYP1A2 inhibitory activity at therapeutic doses. These are the preferred choices for a woman on fezolinetant who needs allergy relief.

Who This Is and Is Not Right For: Life-Stage Guide

Perimenopausal Women (Typical Age 45-52)

This is the life stage where the Veozah-diphenhydramine conflict is most clinically acute. You may still have irregular periods and residual fertility, which means contraception remains relevant. Night sweats are the primary symptom driving fezolinetant use, and sleep deprivation is severe enough that reaching for an over-the-counter sleep aid feels urgent. Use the tiered alternatives above and tell your prescriber you are struggling with sleep so they can supervise any adjunct therapy.

Postmenopausal Women (12 or More Months After Final Period)

Pregnancy is no longer a concern, but anticholinergic sensitivity often increases with age. Women in their late 50s and early 60s on fezolinetant should be especially cautious about adding diphenhydramine, not only because of the CYP1A2 interaction but also because diphenhydramine's cognitive and urinary side effects worsen with lower estrogen. Genitourinary syndrome of menopause (GSM) already raises the risk of urinary symptoms; diphenhydramine's anticholinergic action can push urinary retention into symptomatic territory.

Women with PCOS

PCOS is not an approved indication for fezolinetant, but some research is exploring NK3 receptor blockade as a potential therapy for PCOS-related LH hypersecretion. Early clinical data suggest fezolinetant reduces LH pulse frequency in women with PCOS. If fezolinetant is used off-label in a younger woman with PCOS, pregnancy status must be confirmed before starting, and the same drug interaction principles apply regardless of life stage.

Women with Liver Disease

Pre-existing hepatic impairment independently raises fezolinetant exposure. The Veozah label states that fezolinetant is not recommended in women with moderate or severe hepatic impairment. Adding a CYP1A2 inhibitor on top of already-impaired fezolinetant clearance is a compounding risk. This combination should be avoided entirely.

The Evidence Gap: What We Do Not Know

Women have been under-represented in pharmacokinetic drug-interaction studies for decades, and fezolinetant is no exception. The CYP1A2 inhibition data that informs the diphenhydramine warning is extrapolated from general CYP1A2 inhibitor pharmacokinetic principles and the fluvoxamine interaction study rather than a head-to-head fezolinetant-plus-diphenhydramine clinical trial. No published study has measured fezolinetant plasma concentrations after concurrent diphenhydramine administration in postmenopausal women.

That gap in direct evidence is not a reason to assume the combination is safe. CYP1A2 inhibition is a class effect that is well validated across dozens of drug pairs. The hepatic signal from the SKYLIGHT trials is real and prospectively documented. The precautionary logic is sound even without a diphenhydramine-specific pharmacokinetic study. But you should know that the warning is mechanism-based extrapolation, not direct clinical trial data in women taking both drugs simultaneously.

The Menopause Society's 2023 position statement on nonhormonal therapies for VMS acknowledges fezolinetant as an effective option and notes the hepatotoxicity monitoring requirement, but does not specifically address the diphenhydramine interaction. This is a gap that clinical practice must bridge with individualized prescriber guidance.

Talking to Your Provider: What to Bring Up

Before your next appointment or telehealth visit, gather the following:

1. A full list of every over-the-counter product you take, including sleep aids, cold medicine, allergy tablets, and PM formulations of pain relievers. Check each ingredient list for diphenhydramine.
2. Your most recent ALT and AST results, or ask when they were last drawn.
3. A description of your sleep difficulties: How often are you waking? Is it the hot flash itself that wakes you, or do you struggle to fall back asleep even after the flush passes? The answer changes the treatment recommendation.
4. Any personal or family history of liver disease, elevated liver enzymes, or alcohol use that your provider should factor in.

"Women taking fezolinetant for vasomotor symptoms need to understand that many common over-the-counter sleep aids are not benign add-ons," notes the WomanRx clinical editorial board. "The hepatic monitoring protocol exists because this drug has a real liver signal. Anything that raises its blood levels deserves serious attention."

The SKYLIGHT 4 open-label extension study, which followed women on fezolinetant for 52 weeks, confirmed that the liver enzyme signal remains present at one year, with ALT elevations greater than three times the upper limit of normal occurring in 1.8 percent of the fezolinetant 45 mg group over the full year. Ongoing CYP1A2 inhibition over that same period would not be inconsequential.

Ask your provider directly: "Are any of my other medications, supplements, or OTC products affecting how my body processes fezolinetant?" That specific question is more likely to get a thorough medication reconciliation than a general request.